[EN] COMPOUNDS AS CD73 INHIBITORS<br/>[FR] COMPOSÉS UTILISÉS EN TANT QU'INHIBITEURS DE CD73
申请人:ADORX THERAPEUTICS LTD
公开号:WO2022090711A1
公开(公告)日:2022-05-05
The present invention relates to compounds of formula I shown below: wherein R1and R2are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine CD73 activity is implicated, such as, for example, cancer.
Disclosed are novel compounds of the formula
Also disclosed are pharmaceutical compositions comprising the compounds of Formula I.
Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I.
Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H
1
receptor antagonist.
PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN
申请人:Aslanian Robert G.
公开号:US20100093692A1
公开(公告)日:2010-04-15
The present invention relates to Compounds of Formula (I), compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) in a patient.
US7300941B2
申请人:——
公开号:US7300941B2
公开(公告)日:2007-11-27
[EN] PIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS PIPÉRIDINES ET LEURS PROCÉDÉS D'UTILISATION
申请人:SCHERING CORP
公开号:WO2008108957A2
公开(公告)日:2008-09-12
[EN] The present invention relates to Compounds of Formula (I), compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) in a patient. [FR] La présente invention concerne des composés de formule (I), des compositions comprenant les composés, et des procédés d'utilisation des composés pour traiter ou prévenir la douleur, le diabète, une complication diabétique, la déficience de la tolérance au glucose (IGT) ou la glycémie à jeun (IFG) chez un patient.